Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
50 participants
OBSERVATIONAL
2017-01-01
2021-12-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
MitraClip for Severe TR
NCT02863549
Early Transcatheter Mitral Valve Repair After Myocardial Infarction
NCT06282042
Real World Expanded Multicenter Study of the MitraClip® System (REALISM)
NCT01931956
A Pan-Canadian, Retrospective Evaluation of MitraClip Safety and Efficacy
NCT03592043
Abrogation of Mitral Regurgitation Using the MitraClip System in High-Risk Patients Unsuitable for Surgery
NCT01431222
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
MitraClip
MitraClip consists in two clip arms and opposing grippers, which can be opened and closed against each other in order to grasp and gain cooptation of MV leaflets at the origin of the regurgitant jet
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Transmural myocardial infarction in the previous 4 weeks (managed under current guideline's recommendations).
* Symptomatic severe mitral regurgitation diagnosed by left ventriculography, transthoracic echo or trans-oesophageal echo. Symptoms may vary form heart failure to cardiogenic shock.
* Symptoms should be stabilized by medical management: iv diuretics, inotropic support, LV assistance devices
* Considered by heart team at high risk for conventional surgery
Exclusion Criteria
* Technical contraindication for access to left atrium
* Patient candidate for emergent heart transplant
* Uncontrolled infection
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Abbott Medical Devices
INDUSTRY
Fundación Investigación Sanitaria en León
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Felipe Fernandez Vazquez
MD PhD
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Rodrigo Estevez-Loureiro, PhD
Role: PRINCIPAL_INVESTIGATOR
University Hospital Leon
Carmelo Grasso, PhD
Role: PRINCIPAL_INVESTIGATOR
Ferraroto Hospital Catania
Jan Van der Heijden, PhD
Role: PRINCIPAL_INVESTIGATOR
St. Antonius Hospital
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
EREMMI
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.